# Endocannabinoid System Clinical Research in Back Pain

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/full-spectrum-cannabis-extract-back-pain/
> **Published:** 2026-04-25T23:27:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:57:30-04:00
> **Clinical Summary:** Explore clinical research on full-spectrum cannabis extract back pain treatment showing meaningful pain reduction and safety in chronic low back pain patients.

---

#### Clinical Takeaway

Chronic low back pain patients treated with VER-01 full-spectrum cannabis extract showed clinically meaningful pain reduction compared to placebo over 12 weeks of double-blind treatment. Safety and tolerability data from the extended follow-up phases support continued investigation of this formulation as a potential alternative to conventional [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) approaches. Current treatment limitations and patient population size indicate this therapeutic area warrants evidence-based exploration.

### #2 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

**Citation:** Karst Matthias et al. *Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.* Nature medicine. 2025. PMID: 41023483.

**Study type:** Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study  | 

**Topic area:** Pain  | 

**CED Score:** 14

Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2

**Quality Gate Alerts:**
- Preclinical only

**Methodological Considerations:**
- Open-label design — placebo effect not excluded

**Abstract:** Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P 

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).